Hypertension and nephrology

[Therapy of pathological phosphate metabolism in chronic kidney disease]

LADÁNYI Erzsébet1, DEÁK György2, TISLÉR András3, SZABÓ András4

FEBRUARY 20, 2018

Hypertension and nephrology - 2018;22(01)

[The Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline update for Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) was published in the summer of 2017 and has become a very important guidance of the complex therapy of patients with CKD. It is well known that, besides infections, cardiovascular diseases in close causal relationship with CKD-MBD are leading mortality factors of patients with CKD. Therefore the publication of the new international guideline is especially important. A Nationwide Professional Advisory Board summoned upon the initiative of the Hungarian team of Sanofi-Aventis had its assembly in September 2017 focusing on the current approaches of the therapy of calcium-phosphate metabolism in CKD patients in Hungary. Board members compared the differences between the 2009 and 2017 KDIGO guidelines and reviewed the 2011 Hungarian CKD-MBD recommendation and the relevant financing protocol. Board members assessed the applicability of the new guideline to current Hungarian practice. As compared to the previous 2009 guideline, although a number of issues were revised and modified in the light of new research and clinical results in the new 2017 guideline, most of the recommendations are still applicable tooure very day practice. It is a fundamental requirement to keep to the new guideline including the modified recommendations to optimize the long term life expectancy and quality of life of patients with CKD. The purpose of this article is to compare the 2009 and 2017 KDIGO guidelines in terms of calcium-phosphate metabolism and the treatment of hyperphosphataemia focusing on the new or modified guideline recommendations in order to assess the feasibility of their implementation in Hungarian practice. Based on available evidence and the new KDIGO guideline, board member sout lined the direction of changes of the Hungarian CKD-MBD protocol and the prescription rules of the related medications.]

AFFILIATIONS

  1. FMC Nefrológiai Központ, Miskolc
  2. Uzsoki Utcai Kórház, III. Sz. Belgyógyászati-Nefrológiai Osztály, Budapest
  3. Semmelweis Egyetem, I. Sz. Belgyógyászati Klinika, Budapest
  4. Semmelweis Egyetem, II. Sz. Gyermekgyógyászati Klinika, Budapest

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[How the recognition and treatment of primary aldosteronism could be improved?]

BAJNOK László

[Practically there were no randomized, controlled trials in the area of PA so far, but recently two such ones have appeared. In addition, both are paradigm- forming; yet not built into (yet?) the expert opinions. In the field of primary aldosteronism (PA), there is a sharp contrast between the world’s leading experts in many areas. There is consensus in respect that hypokalaemia, therapy resistance and vascular complications are more common in PA than in primary hypertension. According to prestigious studies, the ratio of surgically correctable cases can be around 5% of hypertension. However, only a tiny fraction of these cases are ever investigated even in the developed countries. Specific treatment might be reached more easily by a multi-speed approach applicable for domestic conditions in which one of the alternatives is the diagnostic process itself. In the latter, following aldosterone criteria are proposed: at screening greater than 15 ng/dl when associated with low renin, in the suppression test, for further testing (adrenal CT) a concentration above 5 ng/dl. This would provide a sufficient balance between sensitivity and specificity. Another solution could be the more widespread use of low dose spironolactone in resistant hypertension.]

Hypertension and nephrology

[The 1st Szekszárd Hypertension Days ]

BENCZÚR Béla

Hypertension and nephrology

[CAVI (Cardio-Ankle Vascular Index) as a Vascular Parameter Independent from Blood Pressure ]

BENCZÚR Béla

Hypertension and nephrology

[The SPRINT Study – Recent Opinions Concerning the SPRINT Study Since the Article “Critical Evaluation and Practical Value of the SPRINT Study Results” was Published in the Journal “Hypertonia és Nephrologia”]

KÉKES Ede, KISS István

Hypertension and nephrology

[Press Release of the Hungarian Society of Hypertension Concerning the New American Hypertension Limit – the Hungarian Limit Remains 140/90 mmHg Still!]

All articles in the issue

Related contents

Hypertension and nephrology

[Hyperkalaemia IV.]

DEÁK György, PATÓ Éva, KÉKES Ede

[The six-part summary presents the epidemiology, diagnosis, pathogenesis, and treatment of hyperkalaemia.]

Ca&Bone

[Calcium and vitamin D supplementation in daily practice in view of contraindications]

KOVÁCS LÁSZLÓ

[The current reimbursement regulations that came into effect this summer for the prevention and the treatment of osteoporosis require calcium and vitamin D supplementation in addition to antiporotic agents if appropriate conditions are met. In this paper, the author reviews those conditions that represent contraindications for calcium and vitamin D supplementation. Among these, the extremely rare vitamin D intoxication is mentioned and a detailed list of disorders resulting in hypercalcaemia is given with emphasis on the most common causes such as hypercalcaemia associated with malignancy and primary hyperparathyroidism. With hypercalcuria and renal stone disease, the diet low in calcium appears to have no effect on the outcome; moreover recent studies demonstrate beneficial effect of increased calcium intake, although the optimal calcium and vitamin D supplementation needs further clarification in these conditions. This review highlights the role of additional factors in increasing the risk such as hyperoxaluria, hyperuricosuria, hypocitraturia, as wells as the excessive protein and potassium-chloride intake or the pharmacological differences of various calcium supplements. The article underscores the use of activated vitamin D products in severe renal failure to prevent secondary hyperparathyroidism and renal osteodystrophy. The new regulations represent a significant improvement in the therapy of patients with osteoporosis, however the individualized therapy and follow up, the good relationship between patient and physician contribute to the optimal therapeutic effects and to minimize the side effects.]

Hungarian Radiology

[Sarcoidosis involving liver and spleen, and with hypercalcemia]

TÓTH Mónika, WENINGER Csaba, MORÓ Zsuzsanna, SZOMOR Árpád

[INTRODUCTION - Sarcoidosis is a relatively common multisystemic disorder. Chest involvement is most frequent, but any organ can be involved. In case of abdominal lesions the suspicion of sarcoidosis rarely arises. CASE REPORT - A 53-year old female patient with a history of crural pain unresponsive to medications and weight loss of unknown origin was sent to the internist. Hypercalcemia and bone pain suggested multiple myeloma, however, this diagnosis could not be confirmed. Chest X-ray examination was negative. Splenomegaly and multiple hypodens splenic and hepatic lesions were detected by ultrasound and abdominal computed tomography. Finally, ultrasound guided biopsy of the liver proved stage II sarcoidosis. Steroid therapy was initiated and the splenic and hepatic lesions seen with ultrasound and CT scan disappeared. CONCLUSION - Sarcoidosis is usually suspected following chest X-ray or during chest CT examination. Nevertheless, our case demonstrates that multiple lesions in the spleen or liver may indicate sarcoidosis even in the absence of thoracic lesions. Biopsy taken from the lesions can lead to adequate diagnosis.]